S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.

Abstract

AIM:

S-1 combined with cisplatin is known to be noninferior to taxanes plus platinum as the first-line treatment for patients with advanced nonsmall cell lung cancer (NSCLC) in the Japanese population. This study aimed to evaluate the efficacy and safety profiles of oral S-1 plus cisplatin (SP) in Taiwanese patients.

METHODS:

Patients with previously untreated stage IIIB or IV NSCLC were prospectively recruited to receive 40-60 mg of S-1 twice daily on days 1-21 plus 60 mg/m2 of cisplatin on day 8 in a 5-week cycle for up to six cycles.

RESULTS:

A total of 55 patients from five cancer centers in Taiwan were enrolled. Among the 46 evaluable patients, those administered with SP achieved disease control rate of 69.6% (partial response, 19.6%; stable disease, 50.0%), with median overall survival and progression-free survival (PFS) of 15.1 and 5.7 months, respectively. Moreover, a better survival trend was observed in epidermal growth factor receptor mutation-positive patients versus mutation-negative patients treated with SP (PFS, 8.6 vs 5.6 months). The most commonly observed treatment-related adverse events (AEs) were nausea (41.8%), followed by decreased appetite, anemia, and diarrhea. Grade of ≥3 AEs related to the study treatment occurred in 11 patients (20.0%). No febrile neutropenia or treatment-related death was found in this study.

CONCLUSIONS:

This study demonstrated that SP is an effective and safe first-line regimen for Taiwanese patients with advanced NSCLC.

• Authors: Chun-Liang Lai, Yu-Fen Wei, Te-Chun Hsia, Gee-Chen Chang, Jiun-Ting Wu, Jung-Yueh Chen, Yuh-Min Chen
• Journal: Asia-Pacific journal of clinical oncology (Asia Pac J Clin Oncol) Vol. 16 Issue 2 Pg. e68-e73 (Apr 2020) ISSN: 1743-7563 [Electronic] Australia
• PMID: 31773897 (Publication Type: Journal Article)
• Copyright: © 2019 John Wiley & Sons Australia, Ltd.

Chemical References

• Antineoplastic Agents
• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology)
• Cisplatin (pharmacology, therapeutic use)
• Drug Combinations
• Female
• Humans
• Lung Neoplasms (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Oxonic Acid (pharmacology, therapeutic use)
• Survival Analysis
• Taiwan
• Tegafur (pharmacology, therapeutic use)